Why the study?
Does pioglitazone prevent nitroglycerin-induced impairment of nitric oxide bioavailability in a rabbit model?
Does pioglitazone prevent nitroglycerin-induced impairment of nitric oxide bioavailability in a rabbit model?
Answers are grounded in this paper and cite their sources.
Pioglitazone prevents nitroglycerin-induced endothelial dysfunction and nitrate tolerance by suppressing nitrosative stress in a rabbit model.
BACKGROUND: We examined whether nitroglycerin (NTG)-induced impairment of nitric oxide (NO) bioavailability could be modified by a peroxisome proliferator-activated receptor (PPAR) gammaagonist. METHODS AND RESULTS: Male New Zealand White rabbits were treated for 7 days with NTG patches, either alone or in combination with pioglitazone. Plasma NO concentration was measured with the catheter-type NO sensor located in the aorta. N(G)-methyl-L-arginine and acetylcholine (ACh) were infused into the aortic arch to measure the basal and ACh-induced plasma NO concentrations. Vascular nitrotyrosine and tetrahydrobiopterin (BH(4)) concentrations were measured by enzyme-linked immunosorbent assay and high-performance liquid chromatography with fluorescence detection, respectively. The negative effects of NTG, that is, the decrease in basal and ACh-induced NO production, were significantly suppressed by co-treatment with pioglitazone. NTG-induced increases in vascular nitrotyrosine and BH(4) concentrations were significantly decreased with co-treatment with pioglitazone. CONCLUSIONS: NTG-induced impairment of basal and ACh-stimulated NO production might be prevented by the co-treatment with a PPAR gamma agonist, pioglitazone through suppressions of nitrosative stress.
No takes yet. Share an insight, caveat, or question.
Ikejima et al. (2008) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: